Basic Information
| LncRNA/CircRNA Name | PSLNR |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | Prostate cancer |
| ICD-0-3 | C61.9 |
| Methods | qPCR, Western blot, RNAi |
| Sample | LNCaP cells, 22RV1, DU145, PC-3, and WPMY-1, tumor tissues and three adjacent normal tissues |
| Expression Pattern | down-regulated |
| Function Description | We reported a novel androgen-reduced prostate-specific lncRNA, PSLNR, that inhibited PCa progression via the p53-dependent pathway. By analyzing the NOCODE data set, we reported that PSLNR was specifically expressed in the prostate, suggesting the potential of PSLNR as a biomarker for PCa treatment. The AR pathway was also confirmed to be an upstream regulation signaling pathway of PSLNR by transcriptionally regulating its expression in androgen-dependent PCa cells. PSLNR also significantly inhibited PCa proliferation by inducing cell apoptosis in a p53-dependent manner. Thus, PSLNR may be a candidate diagnosis and therapeutic target for PCa. |
| Pubmed ID | 31269242 |
| Year | 2019 |
| Title | A novel androgen-reduced prostate-specific lncRNA, PSLNR, inhibits prostate-cancer progression in part by regulating the p53-dependent pathway |
External Links
| Links for PSLNR | GenBank HGNC NONCODE |
| Links for Prostate cancer | OMIM COSMIC |